Sales results disclosed Tuesday raised concern that investors may have overestimated the demand for Zepbound and Mounjaro.

Shares of Eli Lilly (LLY) have dopped to a price level that ... of technical analysts and traders has made it our Stock of the Day. As you can see on the chart, there has been support around ...

(Reuters) -Eli Lilly's stock tumbled 8% on Tuesday after it forecast fourth-quarter sales of weight-loss drug Zepbound below Wall Street estimates, marking the second time sales have disappointed ...

The company's shares were trading at $739.23, on track for their worst single-day decline in nearly four years. Copenhagen-listed rival Novo Nordisk's shares also fell 3.5%. Lilly's stock went on ...

On Wednesday, the FDA approved Eli Lilly And Co’s (NYSE:LLY) Omvoh (mirikizumab-mrkz) for moderately to severely active Crohn’s disease in adults. Omvoh is now approved in the U.S. for two ...